Evaluation of the Effectiveness of Boron Neutron Capture Therapy with Iodophenyl-Conjugated
boron compound
boron neutron capture therapy (BNCT)
closo-dodecaborate
high-grade glioma
radiological experimental studies
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
15 Sep 2023
15 Sep 2023
Historique:
received:
08
08
2023
revised:
12
09
2023
accepted:
13
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
High-grade gliomas present a significant challenge in neuro-oncology because of their aggressive nature and resistance to current therapies. Boron neutron capture therapy (BNCT) is a potential treatment method; however, the boron used by the carrier compounds-such as 4-borono-L-phenylalanine (L-BPA)-have limitations. This study evaluated the use of boron-conjugated 4-iodophenylbutanamide (BC-IP), a novel boron compound in BNCT, for the treatment of glioma. Using in vitro drug exposure experiments and in vivo studies, we compared BC-IP and BPA, with a focus on boron uptake and retention characteristics. The results showed that although BC-IP had a lower boron uptake than BPA, it exhibited superior retention. Furthermore, despite lower boron accumulation in tumors, BNCT mediated by BC-IP showed significant survival improvement in glioma-bearing rats compared to controls (not treated animals and neutrons only). These results suggest that BC-IP, with its unique properties, may be an alternative boron carrier for BNCT. Further research is required to optimize this potential treatment modality, which could significantly contribute to advancing the treatment of high-grade gliomas.
Identifiants
pubmed: 37759639
pii: biology12091240
doi: 10.3390/biology12091240
pmc: PMC10525593
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP23H03024
Références
Jpn J Clin Oncol. 2022 May 5;52(5):433-440
pubmed: 35079791
Am J Physiol. 1992 Jan;262(1 Pt 2):H246-54
pubmed: 1733316
Cells. 2022 Sep 01;11(17):
pubmed: 36078143
J Clin Oncol. 2005 Nov 1;23(31):7794-803
pubmed: 16172456
J Neurosci Methods. 2016 Feb 1;259:47-56
pubmed: 26617320
Pharmaceutics. 2022 May 22;14(5):
pubmed: 35631692
Int J Biol Macromol. 2019 Oct 1;138:602-617
pubmed: 31319084
Appl Radiat Isot. 2004 Nov;61(5):1069-73
pubmed: 15308194
Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):643-52
pubmed: 7928496
J Med Chem. 2000 Apr 6;43(7):1253-6
pubmed: 10753462
Cancer Chemother Pharmacol. 2002 Apr;49(4):342-5
pubmed: 11914915
Adv Drug Deliv Rev. 2008 May 22;60(8):876-85
pubmed: 18423779
Cancer Res. 2009 Mar 1;69(5):2126-32
pubmed: 19244126
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
J Med Invest. 2014;61(3-4):254-63
pubmed: 25264042
J Control Release. 2016 Sep 10;237:160-7
pubmed: 27422608
Clin Cancer Res. 2012 Jul 15;18(14):3856-67
pubmed: 22619306
Mol Aspects Med. 2012 Jun;33(3):209-90
pubmed: 22230555
Transfus Med Hemother. 2016 May;43(3):223-32
pubmed: 27403094
Invest New Drugs. 2022 Apr;40(2):255-264
pubmed: 34816337
J Control Release. 2012 Jan 10;157(1):4-28
pubmed: 21959118
Chem Soc Rev. 2016 Mar 7;45(5):1432-56
pubmed: 26771036
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
J Radiat Res. 2014 Jan 1;55(1):146-53
pubmed: 23955053
Life (Basel). 2022 Jul 20;12(7):
pubmed: 35888170
Pharmaceutics. 2022 Mar 28;14(4):
pubmed: 35456562
Inorg Chem. 2018 Mar 5;57(5):2333-2350
pubmed: 29465227
ACS Nano. 2016 Nov 22;10(11):9999-10012
pubmed: 27934069
Cells. 2021 Oct 26;10(11):
pubmed: 34831103
Cancer Commun (Lond). 2018 Jun 19;38(1):35
pubmed: 29914561
Org Biomol Chem. 2019 Jun 5;17(22):5496-5499
pubmed: 30976763
Cancer Lett. 2008 Apr 18;262(2):143-52
pubmed: 18313207
Int J Rad Appl Instrum B. 1990;17(8):819-27
pubmed: 2079429
Radiat Res. 1999 Jan;151(1):1-18
pubmed: 9973079
Clin Cancer Res. 1999 Apr;5(4):753-9
pubmed: 10213209
Radiat Res. 2003 Jul;160(1):70-6
pubmed: 12816525
J Neurooncol. 1998 Jan;36(1):91-102
pubmed: 9525831
Biology (Basel). 2023 Feb 27;12(3):
pubmed: 36979069
Crit Rev Oncol Hematol. 1997 Jul;26(2):77-100
pubmed: 9298326
J Control Release. 2012 Jan 30;157(2):168-82
pubmed: 21839127
Int J Mol Sci. 2020 Jun 30;21(13):
pubmed: 32630060
J Clin Oncol. 2009 Aug 1;27(22):3611-9
pubmed: 19470941
J Neurooncol. 2009 Sep;94(3):299-312
pubmed: 19381449
Front Oncol. 2021 Feb 26;11:601820
pubmed: 33718149
Bioorg Med Chem Lett. 2022 Sep 15;72:128869
pubmed: 35772634
J Clin Neurosci. 2011 Sep;18(9):1163-7
pubmed: 21745745
Biology (Basel). 2020 Dec 01;9(12):
pubmed: 33271972
Chem Rev. 1998 Jun 18;98(4):1515-1562
pubmed: 11848941
Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1121-9
pubmed: 8262837
Anticancer Drugs. 1997 Aug;8(7):677-85
pubmed: 9311444